MDXG News and Press, MiMedx Group Inc From 11/01/22

MiMedx Group ( NASDAQ: MDXG ) is scheduled to announce Q3 earnings results on Wednesday, November 2nd, after market close. The consensus EPS Estimate is -$0.12 (-200.0% Y/Y) and the consensus Revenue Estimate is $66.73M (+5.8% Y/Y). Over the last 3 months, EPS estimate...

MARIETTA, Ga., Oct. 19, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that it will report operating and financial results for the third quarter ended Septemb...

Experienced Healthcare-focused Financial and Communications Leader to Strengthen and Expand Relationships with Investment Community MARIETTA, Ga., Oct. 04, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ: MDXG) (“MIMEDX” or the “Company”), a transformatio...

Adds a Unique Collagen Matrix Particulate Derived from Human-Placental Tissue to the Growing $1B Surgical Recovery Market MARIETTA, Ga., Sept. 20, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformation...

New Product Enables Company to Target Additional Surgical Procedures and Deepen Market Penetration in the Growing $1B Surgical Recovery Market MARIETTA, Ga., Sept. 19, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”...

MiMedx ( NASDAQ: MDXG ) on Monday said it had gotten Japanese approval for the reimbursement of its EPIFIX tissue allograft for the treatment of lower extremity diabetic and venous ulcers. The reimbursement decision came from the Japanese Ministry of Health, Labor and Welf...

Provides Favorable Access to a New $500 Million Market for the Treatment of Refractory Diabetic and Venous Ulcers for EPIFIX – the First and Only Amniotic Tissue Product Approved for Use in Japan MARIETTA, Ga., Sept. 12, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: ...

MiMedx Group ( NASDAQ: MDXG ) provided an update on its revenue outlook for 2022, expecting net sales of its continuing portfolio of Advanced Wound Care (AWC) products in the low end of 11%-14% growth range. The placental biologics company has seen softer sales of its prod...

K. Todd Newton Appointed as Interim Chief Executive Officer, Replacing Timothy R. Wright, Effective Immediately MARIETTA, Ga., Sept. 06, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental...

The Cato T. Laurencin Regenerative Engineering Founders’ Award Promotes Advancement of Scientific Leadership and Research in the Field of Regenerative Engineering MARIETTA, Ga., Aug. 26, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or t...